No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.

Abstract

The combination of glecaprevir (formerly ABT-493), a nonstructural protein 3/4A (NS3/4A) protease inhibitor, and pibrentasvir (formerly ABT-530), an NS5A protein inhibitor, is being developed as treatment for HCV genotype 1 to 6 infection. The pharmacokinetics, pharmacodynamics, safety, and tolerability of methadone or buprenorphine-naloxone when… (More)
DOI: 10.1128/AAC.00958-17

Topics

Cite this paper

@article{Kosloski2017NoCR, title={No Clinically Relevant Drug-Drug Interactions between Methadone or Buprenorphine-Naloxone and Antiviral Combination Glecaprevir and Pibrentasvir.}, author={Matthew P. Kosloski and Weihan Zhao and Armen Asatryan and Jens J. Kort and Pierre A Geoffroy and Wei Liu}, journal={Antimicrobial agents and chemotherapy}, year={2017}, volume={61 10} }